article · Medicina
Metabolic syndrome and insulin resistance can lead to diabetes and cardiovascular complications, with overactive cannabinoid receptor-1 (CB1) implicated in these conditions. This study evaluated the effects of two CB1 neutral antagonists, the peripherally acting AM6545 and the centrally acting AM4113, in male rats fed a high-fructose and high-salt diet for twelve weeks. Administering either compound during the final four weeks significantly reduced insulin resistance, decreased body weight, and lowered elevated serum cholesterol, triglycerides, and uric acid. Both treatments also counteracted the diet-induced decline in adiponectin and reduced liver TNF alpha levels, reflecting anti-inflammatory benefits. Overall, both central and peripheral CB1 neutral antagonists demonstrated comparable abilities to alleviate insulin resistance and correct metabolic disturbances, indicating that targeting these receptors may offer a path for managing metabolic syndrome.
Insulin resistance is a major contributor to severe health problems such as type 2 diabetes and heart disease. Finding compounds that improve metabolic profiles without adverse side effects is essential. By demonstrating that specific CB1 receptor blockers can reduce body weight, lower blood lipids, and curb inflammation, this study highlights viable therapeutic mechanisms for controlling metabolic disorders.
This research provides early-stage preclinical evidence in an animal model that may inform pharmaceutical drug discovery programmes focusing on metabolic syndrome and type 2 diabetes. The findings could be useful for drug developers seeking CB1 neutral antagonists with improved safety profiles. However, the work remains at an early laboratory stage and is far from clinical or real-world use.
AI-generated from the published abstract. Always read the original work before citing.
<i>Background and Objectives:</i> Insulin resistance (IR) is a serious condition leading to development of diabetes and cardiovascular complications. Hyper-activation of cannabinoid receptors-1 (CB1) has been linked to the development of metabolic disorders such as IR. Therefore, the effect of blocking CB1 on the development of IR was investigated in the present study. <i>Materials and Methods:</i> A 12-week high-fructose/high-salt feeding model of metabolic syndrome was used to induce IR in male Wistar rats. For this purpose, two different CB1-antagonists were synthesized and administered to the rats during the final four weeks of the study, AM6545, the peripheral neutral antagonist and AM4113, the central neutral antagonist. <i>Results:</i> High-fructose/salt feeding for 12 weeks led to development of IR while both AM6545 and AM4113, administered in the last 4 weeks, significantly inhibited IR. This was correlated with increased animal body weight wherein both AM6545 and AM4113 decreased body weight in IR animals but with loss of IR/body weight correlation. While IR animals showed significant elevations in serum cholesterol and triglycerides with no direct correlation with IR, both AM6545 and AM4113 inhibited these elevations, with direct IR/cholesterol correlation in case of AM6545. IR animals had elevated serum uric acid, which was reduced by both AM6545 and AM4113. In addition, IR animals had decreased adiponectin levels and elevated liver TNFα content with strong IR/adiponectin and IR/TNFα correlations. AM6545 inhibited the decreased adiponectin and the increased TNFα levels and retained the strong IR/adiponectin correlation. However, AM4113 inhibited the decreased adiponectin and the increased TNFα levels, but with loss of IR/adiponectin and IR/TNFα correlations. <i>Conclusions:</i> Both CB1 neutral antagonists alleviated IR peripherally, and exerted similar effects on rats with metabolic syndrome. They also displayed anti-dyslipidemic, anti-hyperurecemic and anti-inflammatory effects. Overall, these results should assist in the development of CB1 neutral antagonists with improved safety profiles for managing metabolic disorders.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/medicina56110573
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
